SureNano Science Ltd

As of June 30, 2026, SureNano Science Ltd carries a market capitalization of 6.30M, placing it among publicly traded companies globally. Its enterprise value stands at 5.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, SureNano Science Ltd has 42.01M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, SureNano Science Ltd maintains a current ratio of 20.89, meaning it holds 20.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -27.03, reflecting losses generated across the asset base.

As of the close on October 20, 2026, SureNano Science Ltd's stock has declined approximately 16.67% over the past 52 weeks. The 50-day moving average sits at 0.16, while the 200-day moving average is 0.18.

Over the twelve months ended June 30, 2026, SureNano Science Ltd generated - - in revenue and converted that into -697,130.00 in net income, yielding earnings per share of -0.02. EBITDA reached -694,630.00, while operating income came in at -697,130.00.

These figures are as of June 30, 2026. Total book value stands at 5.09M, with working capital of 710,693.00 providing operational flexibility.

SureNano Science Ltd produced -624,758.00 in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -12.63: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -21.17, meaning SureNano Science Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, SureNano Science Ltd has an Altman Z-Score of 98.83, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.